Osorio Alvaro, Fernandez-Trujillo Liliana, Restrepo Juan G, Sua Luz F, Proaño Catalina, Zuñiga-Restrepo Valeria
Department of Internal Medicine, Oncology Service, Fundación Valle Del Lili, Cali, Colombia.
Faculty of Health Sciences, Universidad Icesi, Cali, Colombia.
Cancer Manag Res. 2024 Jul 11;16:781-789. doi: 10.2147/CMAR.S455809. eCollection 2024.
Lung cancer is the leading cause of cancer-related deaths worldwide. However, with the optimization of screening strategies and advances in treatment, mortality has been decreasing in recent years. In this study, we describe non-small cell lung cancer patients diagnosed between 2021 and 2022 at a high-complexity hospital in Latin America, as well as the immunohistochemistry techniques used to screen for rearrangements, in the context of the recent approval of crizotinib for the treatment of rearrangements in non-small cell lung cancer in Colombia.
A descriptive cross-sectional study was conducted. Sociodemographic, clinical, and molecular pathology information from non-small cell lung cancer individuals who underwent immunohistochemistry to detect rearrangements between 2021 and 2022 at Fundación Valle del Lili (Cali, Colombia) was recorded. The clinical outcomes of confirmed rearrangements in non-small cell lung cancer patients were reported.
One hundred and thirty-six patients with non-small cell lung cancer were included. The median age at diagnosis was 69.8 years (interquartile range 61.9-77.7). At diagnosis, 69.8% (n = 95) were at stage IV. immunohistochemistry was performed using the monoclonal D4D6 antibody clone in 54.4% (n = 74) of the cases, while 45.6% (n = 62) were done with the monoclonal SP384 antibody clone. Two patients were confirmed to have rearrangements in non-small cell lung cancer using next-generation sequencing and received crizotinib. On follow-up at months 5.3 and 7.0, one patient had a partial response, and the other had oligo-progression, respectively.
Screening for rearrangements in non-small cell lung cancer is imperative, as multiple prospective studies have shown improved clinical outcomes with tyrosine kinase inhibitors. Given the recent approval of crizotinib in Colombia, public health policies must be oriented toward early detection of driver mutations and prompt treatment. Additionally, future approvals of newly tested tyrosine kinase inhibitors should be anticipated.
肺癌是全球癌症相关死亡的主要原因。然而，随着筛查策略的优化和治疗的进展，近年来死亡率一直在下降。在本研究中，我们描述了2021年至2022年期间在拉丁美洲一家高复杂性医院诊断出的非小细胞肺癌患者，以及在克唑替尼最近在哥伦比亚被批准用于治疗非小细胞肺癌重排的背景下，用于筛查重排的免疫组织化学技术。
进行了一项描述性横断面研究。记录了2021年至2022年在Fundación Valle del Lili（哥伦比亚卡利）接受免疫组织化学检测重排的非小细胞肺癌患者的社会人口统计学、临床和分子病理学信息。报告了非小细胞肺癌患者确诊重排的临床结果。
纳入了136例非小细胞肺癌患者。诊断时的中位年龄为69.8岁（四分位间距61.9 - 77.7）。诊断时，69.8%（n = 95）为IV期。54.4%（n = 74）的病例使用单克隆D4D6抗体克隆进行免疫组织化学检测，而45.6%（n = 62）使用单克隆SP384抗体克隆进行检测。两名患者通过下一代测序确诊为非小细胞肺癌重排，并接受了克唑替尼治疗。在5.3个月和7.0个月的随访中，一名患者有部分缓解，另一名患者有寡进展。
对非小细胞肺癌重排进行筛查至关重要，因为多项前瞻性研究表明酪氨酸激酶抑制剂可改善临床结果。鉴于克唑替尼最近在哥伦比亚获得批准，公共卫生政策必须着眼于驱动突变的早期检测和及时治疗。此外，应预期新测试的酪氨酸激酶抑制剂未来会获得批准。
